

February 28, 2013



# Amarantus BioScience to Present MANF Parkinson's Data at the 15th Annual American Society for Experimental NeuroTherapeutics

SUNNYVALE, Calif., Feb. 28, 2013 /PRNewswire/ -- Amaranthus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Dr. John W. Commissiong, Chief Scientific Officer, will be presenting data generated in six hydroxydopamine (6-OHDA) rodent models of Parkinson's disease at the 15<sup>th</sup> Annual Meeting of the American Society for Experimental NeuroTherapeutics (ASENT) in Washington, DC on March 1<sup>st</sup>, 2013. The meeting is being held February 28 – March 2, 2013 at the Hyatt Regency in Bethesda, Maryland.

"There is tremendous interest in our progress in Parkinson's disease research, and I look forward to meeting with leading researchers and industry professionals to discuss the important results we are seeing in our studies with MANF," said Dr. Commissiong. "ASENT is an outstanding forum to interact with colleagues, and stay apprised of the latest research in this field."

## **About ASENT**

The American Society for Experimental NeuroTherapeutics is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.

ASENT engages in scientific exchanges to encourage contacts between those involved in the discovery and development of neurotherapeutics and to provide opportunities for dialogue between the interested groups. The society organizes education and training and publishes a journal for healthcare practitioners, scientists and officials participating in the neurotherapeutics field, which serves as a forum for its members and interested groups addressing diverse issues.

## **About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)**

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of

reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amaranthus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amaranthus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.

### **About Amaranthus BioScience, Inc.**

Amaranthus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit [www.Amaranthus.com](http://www.Amaranthus.com).

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amaranthus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amaranthus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amaranthus' new product candidates, including those identified under "Risk Factors" in Amaranthus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amaranthus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amaranthus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

### **MEDIA CONTACTS**

#### **Amaranthus Bioscience, Inc.**

(408) 737-2734

[pr@amaranthus.com](mailto:pr@amaranthus.com)

#### **Investor/Media Contact:**

IR Sense, LLC

Remy Bernarda

(408) 737-2734 x109

[remy@irsense.com](mailto:remy@irsense.com)

SOURCE Amaranthus BioScience, Inc.